Dermatology To Become A Key Franchise For Incyte
Topical Formulation Of Ruxolitinib On Fast Track For Vitiligo
Executive Summary
Having just launched Opzelura in the US for atopic dermatitis, the US biotech is hoping for another approval in the next few months for its topical JAK inhibitor, this time for vitiligo.
You may also be interested in...
Incyte Signals Increasing Focus In Dermatology With Villaris Buyout
With Opzelura approved for vitiligo in July, Incyte acquires Villaris and its preclinical IL-15-targeted antibody to potentially add to its vitiligo portfolio.
Clinuvel Plots Competition To Incyte In Vitiligo Space
The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.
Wild Ride For Immunology? New Mechanisms, Big Indications Up For US FDA Approval In 2022
Major R&D efforts in immuno-dermatology produced multiple novel candidates in atopic dermatitis and psoriasis, while alopecia areata and vitiligo might see first therapies and JAK safety and COVID-19 logjams resolve.